Dasiglucagon Shows Promise in Mitigating Hypoglycemia after bariatric surgery
In a significant development for individuals grappling with postbariatric hypoglycemia after Roux-en-Y gastric bypass surgery, dasiglucagon, a stable glucagon analog, has demonstrated substantial effectiveness in a recent outpatient trial. The condition, affecting over 50% of those who undergo the surgery, has limited treatment options, making this research a potential game-changer. This study was published in the journal Diabetes Care by Casper K. and colleagues.
Conducted at the Center for Clinical Metabolic Research at Gentofte Hospital in Denmark, the study employed a randomized, double-blind, placebo-controlled, crossover, proof-of-concept approach. Twenty-four individuals, predominantly women, with verified postbariatric hypoglycemia were assigned to two treatment periods involving 4 weeks of self-administered subcutaneous dasiglucagon at 120 μg or a placebo. The primary outcomes were measured through continuous glucose monitoring, focusing on the percentage of time spent in level 1 and 2 hypoglycemia.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.